A Potential Revolutionary Treatment: The Theoretical Foundation and Research Progress of Whole Brain Radiotherapy Combined with Erlotinib in Treatment for Multiple Brain Metastases of Lung Adenocarcinoma
Tyrosine kinase inhibitors (TKI) has brought revolutionary change for the treatment of lung adenocarcinoma, and the theoretical basis is sufficient of whole brain radiotherapy (WBRT)combined with erlotinib in treatment for brain metastasis of lung adenocarcinoma.In theory, it is a potential revolutionary treatment and the optimal indication of TKI concurrent with radiotherapy in lung adenocarcinoma.However, there is no difference in the treatment for brain metastasis especially for multiple brain metastases between lung adenocarcinoma and other lung carcinomas now.Furthermore, clinical trials of combination of TKI and WBRT as treatment to multiple metastasis of lung adenocarcinoma is limited, many clinical questions need to be solved.Lung adenocarcinoma is characterized by high possibility of brain metastasis and target therapy has been widely used in clinical treatment, as a result clinical trials are needed to provide proof to support the combination of erlotinib and WBRT.
EGFR Erlotinib Radiotherapy Brain metastasis Lung adenocarcinoma
Hong-qing Zhuang Jun-jie Wang
Department of Radiotherapy, Tianjin Medical University Cancer Institute and Hospital, Tianjin Key La Department of Radiotherapy, Peking Third Hospital, Beijing, China
国内会议
北京大学医学部放射肿瘤学系成立大会暨北京大学第二届国际放射肿瘤学术论坛
北京
英文
32-44
2012-05-23（万方平台首次上网日期，不代表论文的发表时间）